St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature

Abstract. Rationale: St. John's wort (Hypericum perforatum) has recently gained popularity as an alternative treatment for mild to moderate depression. Given the current widespread use of this herbal remedy, it is important for medical professionals to understand the potential pharmacological pathways through which Hypericum may exert an antidepressant effect. Objectives: (1) To review the current pharmacological, toxicological, and clinical literature available on Hypericum, and (2) to provide a synthesis of this information into a form that may be easily used by health care providers. Method: A comprehensive review of the recent scientific literature (January 1990–March 2000) was performed using the following electronic databases and reference publications: MEDLINE, The Cochrane Library, HealthSTAR, Current Contents (all editions), European Scientific Cooperative on Phytotherapy monographs, German Commission E monographs, and the Physicians' Desk Reference for Herbal Medicines, 1st edition. Results: One hundred and seven (107) publications in the English language and three publications in German were included in the review. Collectively, the data suggest that therapeutic preparations of Hypericum extract appear to exert potentially significant pharmacological activity within several neurochemical systems believed to be implicated in the pathophysiology of depression. However, little information exists regarding the safety of Hypericum, including potential herb–drug interactions. Conclusions: Additional research on the pharmacological and biochemical activity of Hypericum and its several bioactive constituents is necessary to further elucidate the mode(s) of antidepressant action. Given what is currently known and unknown about the biological properties of Hypericum, those who choose to use this herb should be closely monitored by a physician.

[1]  S S Chatterjee,et al.  Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. , 1998, Pharmacopsychiatry.

[2]  M. Groves Hypericum perforatum L. , 1998 .

[3]  S. Frokjaer,et al.  High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. , 1988, Biochemical pharmacology.

[4]  H. Wagner,et al.  Inhibition of type A and type B monoamine oxidases by naturally occurring xanthones. , 1981, Planta medica.

[5]  J. Falloon,et al.  Indinavir concentrations and St John's wort , 2000, The Lancet.

[6]  R. Kessler,et al.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. , 1998, JAMA.

[7]  O. Krishtal,et al.  Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. , 1999, Life sciences.

[8]  P. Cowen,et al.  Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers , 1999, Biological Psychiatry.

[9]  A. Nahrstedt,et al.  Biologically Active and Other Chemical Constituents of the Herb of Hypericum perforatum L. , 1997, Pharmacopsychiatry.

[10]  W. Müller,et al.  Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. , 1995, Arzneimittel-Forschung.

[11]  E. Ernst St. John's Wort, an anti-depressant? A systematic, criteria-based review. , 1995, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  J. Cott In Vitro Receptor Binding and Enzyme Inhibition by Hypericum perforatum Extract , 1997, Pharmacopsychiatry.

[13]  S. Risch,et al.  Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.

[14]  R. Kaufmann,et al.  Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. , 1999, Photochemistry and photobiology.

[15]  E. Esposito,et al.  Effect of Acute Administration of Hypericum Perforatum-CO2 Extract on Dopamine and Serotonin Release in the Rat Central Nervous System , 2000, Pharmacopsychiatry.

[16]  G. Bove Acute neuropathy after exposure to sun in a patient treated with St John's Wort , 1998, The Lancet.

[17]  A. Nahrstedt,et al.  Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. , 1998, Planta medica.

[18]  Y. Öztürk Testing the antidepressant effects of Hypericum species on animal models. , 1997 .

[19]  J. Cott Medicinal plants and dietary supplements: sources for innovative treatment or adjuncts? , 1995, Psychopharmacology bulletin.

[20]  L. S. Koupparis Harmless herbs: a cause for concern? , 2000, Anaesthesia.

[21]  R. Scholten,et al.  The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines , 1999, Annals of Internal Medicine.

[22]  N. Fineberg,et al.  SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OCD , 1992, Clinical neuropharmacology.

[23]  U. Hafner,et al.  Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. , 1998, Pharmacopsychiatry.

[24]  W. Muller,et al.  JOHANNISKRAUT : IN-VITRO-STUDIE UBER HYPERICUM-EXTRAKT, HYPERICIN UND KAMPFEROL ALS ANTIDEPRESSIVA , 1996 .

[25]  Y. Oztürk Testing the antidepressant effects of Hypericum species on animal models. , 1997, Pharmacopsychiatry.

[26]  M. Ploch,et al.  Modulation of Cytokine Expression by Hypericum Extract , 1994 .

[27]  V. Giambanco,et al.  St. John's Wort and Antidepressant Drug Interactions in the Elderly , 1999, Journal of geriatric psychiatry and neurology.

[28]  A. Fugh-Berman,et al.  Dietary supplements and natural products as psychotherapeutic agents. , 1999, Psychosomatic medicine.

[29]  J. Brockmöller,et al.  Hypericin and Pseudohypericin: Pharmacokinetics and Effects on Photosensitivity in Humans , 1997, Pharmacopsychiatry.

[30]  M Kieser,et al.  St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. , 1998, Pharmacopsychiatry.

[31]  J. Brockmöller,et al.  Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin , 1996, Antimicrobial agents and chemotherapy.

[32]  U. Hafner,et al.  Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. , 1997, Pharmacopsychiatry.

[33]  P. Cowen,et al.  Antidepressant-like effect of Hypericum perforatum (St John’s wort) on the sleep polysomnogram , 1998, Psychopharmacology.

[34]  J. Vry,et al.  Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism , 1999, European Neuropsychopharmacology.

[35]  J. Neary,et al.  Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes , 1999, Brain Research.

[36]  J. Streltzer,et al.  St. John's wort for depression: a meta-analysis of well-defined clinical trials. , 1999, The Journal of nervous and mental disease.

[37]  F. Firenzuoli,et al.  Effects of Hypericum perforatum on Levels of 5‐Hydroxytryptamine, Noradrenaline and Dopamine in the Cortex, Diencephalon and Brainstem of the Rat , 1999, The Journal of pharmacy and pharmacology.

[38]  A. Burstein,et al.  St John's Wort: Effect on CYP3A4 activity , 2000 .

[39]  H M Thiede,et al.  Inhibition of MAO and COMT by hypericum extracts and hypericin. , 1994, Journal of geriatric psychiatry and neurology.

[40]  H. Wagner,et al.  Inhibition of monoamine oxidase by hypericin. , 1984, Planta medica.

[41]  D. Overstreet,et al.  Attenuation of alcohol intake by extract of Hypericum perforatum (St. John's Wort) in two different strains of alcohol-preferring rats. , 1999, Alcohol and alcoholism.

[42]  V. Zlotnik,et al.  Neuropharmacology of St. John's Wort (Hypericum) , 1998, The Annals of pharmacotherapy.

[43]  S. Okpanyi,et al.  [Genotoxicity of a standardized Hypericum extract]. , 1990, Arzneimittel-Forschung.

[44]  S. Mace,et al.  Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression , 2000, Expert opinion on pharmacotherapy.

[45]  S. Chatterjee,et al.  Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers , 1998, Pharmacopsychiatry.

[46]  S. Bhattacharya,et al.  Hyperforin as a possible antidepressant component of hypericum extracts. , 1998, Life sciences.

[47]  S. Kaehler,et al.  Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus , 1999, Neuroscience Letters.

[48]  B. Gaster,et al.  St John's wort for depression: a systematic review. , 2000, Archives of internal medicine.

[49]  W. Dimpfel,et al.  Pharmacodynamic Effects of two Different Hypericum Extracts in Healthy Volunteers Measured by Quantitative EEG , 1998, Pharmacopsychiatry.

[50]  I. Roots,et al.  Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.

[51]  H. Schulz,et al.  Effects of hypericum extract on the sleep EEG in older volunteers. , 1994, Journal of geriatric psychiatry and neurology.

[52]  J. Brockmöller,et al.  Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. , 1994, Journal of geriatric psychiatry and neurology.

[53]  G. Pepeu,et al.  [Monoamine oxidase inhibitors in the aged]. , 1964, Giornale di gerontologia. Supplemento.

[54]  W. Müller,et al.  Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. , 1999, The Journal of pharmacology and experimental therapeutics.

[55]  C. Erdelmeier Hyperforin, Possibly the Major Non-Nitrogenous Secondary Metabolite of Hypericum perforatum L. , 1998, Pharmacopsychiatry.

[56]  M. Nöldner,et al.  Antidepressant Activity of Hypericum Perforatum and Hyperforin: the Neglected Possibility , 1998, Pharmacopsychiatry.

[57]  C. Mulrow,et al.  St John's wort for depression—an overview and meta-analysis of randomised clinical trials , 1996, BMJ.

[58]  H. Schulz,et al.  Memory self-report in Alzheimer's disease and in age-associated memory impairment. , 1994 .

[59]  E. Elstner,et al.  Biochemical Activities of Extracts from Hypericum perforatum L. 1st Communication: Inhibition of dopamine - β - hydroxylase , 1999, Arzneimittelforschung.

[60]  J. Deltito,et al.  The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. , 1998, Journal of affective disorders.

[61]  W. Burkard,et al.  Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. , 1997, Pharmaceutica acta Helvetiae.

[62]  H. Wagner,et al.  Inhibition of MAO by Fractions and Constituents of Hypericum Extract , 1994 .

[63]  E. Ernst,et al.  Second thoughts about safety of St John's wort , 1999, The Lancet.

[64]  H. Wagner,et al.  Pharmaceutical Quality of Hypericum Extracts , 1994, Journal of geriatric psychiatry and neurology.

[65]  C. Miranda,et al.  Consumption of poisonous plants (Senecio jacobaea, Symphytum officinale, Pteridium aquilinum, Hypericum perforatum) by rats: chronic toxicity, mineral metabolism, and hepatic drug-metabolizing enzymes. , 1982, Toxicology letters.

[66]  A. Nierenberg,et al.  Mania associated with St. John’s wort , 1999, Biological Psychiatry.

[67]  G. Harrer,et al.  Comparison of Equivalence between the St. John’s Wort Extract LoHyp-57 and Fluoxetine , 1999, Arzneimittelforschung.

[68]  R. Valentino,et al.  Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. , 1991, Progress in brain research.

[69]  J. Vetulani,et al.  Mode of action of antidepressant drugs. , 1978, Biochemical pharmacology.

[70]  John A. Astin Why Patients Use Alternative Medicine: Results of a National Study , 1999 .

[71]  J. Yager,et al.  Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues. , 1999, The American journal of psychiatry.

[72]  E. Ernst,et al.  Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.) , 1998, European Journal of Clinical Pharmacology.

[73]  S H Snyder,et al.  Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. , 1980, Science.

[74]  J. Pepping St. John's wort: Hypericum perforatum. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[75]  J. Gleitz,et al.  Effects of Long-Term Administration of Hypericum Extracts on the Affinity and Density of the Central Serotonergic 5-HT1 A and 5-HT2 A Receptors , 1997, Pharmacopsychiatry.

[76]  M. Gobbi,et al.  Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[77]  Cott Jm Medicinal plants and dietary supplements: sources for innovative treatment or adjuncts? , 1995 .

[78]  J. Simon,et al.  Hypericin Levels in Human Serum and Interstitial Skin Blister Fluid after Oral Single-Dose and Steady-State Administration of Hypericum perforatum Extract (St. John’s Wort) , 1999, Skin Pharmacology and Physiology.

[79]  W. Dimpfel,et al.  Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG). , 1998, Pharmacopsychiatry.

[80]  R. Ciccocioppo,et al.  Effects of Hypericum perforatum extraction on alcohol intake in Marchigian Sardinian alcohol-preferring rats. , 1999, Alcohol and alcoholism.

[81]  A. Nahrstedt,et al.  Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. , 1997, Pharmacopsychiatry.

[82]  W. Dimpfel,et al.  Central action of hyperici herba cum flore extractum siccum in freely moving rats. , 1997, European Journal of Medical Research.

[83]  A. Holtz,et al.  Fluoxetine tenth anniversary update: the progress continues. , 1997, Clinical therapeutics.

[84]  H. Woelk,et al.  Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. , 1994, Journal of geriatric psychiatry and neurology.

[85]  L. Cohen,et al.  St John's wort during pregnancy. , 1998, JAMA.

[86]  Dr. Peter H. Yu Effect of the Hypericum Perforatum Extract on Serotonin Turnover in the Mouse Brain , 2000, Pharmacopsychiatry.

[87]  S. Priebe,et al.  Assessing the quality of psychiatric hospital care: a German approach. , 1998, Psychiatric services.

[88]  S. Ettner,et al.  Trends in alternative medicine use in the United States , 1999 .

[89]  R. Raffa Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. , 1998, Life sciences.

[90]  C. Gambarana,et al.  Efficacy of an Hypericum Perforatum (St. John's Wort) Extract in Preventing and Reverting a Condition of Escape Deficit in Rats , 1999, Neuropsychopharmacology.

[91]  J. Tuomisto,et al.  Neurotransmitter regulation of anterior pituitary hormones. , 1985, Pharmacological reviews.